Prevention efficacy and pharmacokinetics of HP6H8. (A) Schedule of the prevention challenge tests in huRBC-engrafted NOG mice. (Bi) Parasitemia, (Bii) inhibition efficacy, and (Biii) the proportion of mice remaining parasitemic after the first P falciparum infection. (Bi-Bii) Lines show doses of HP6H8 at 0.016, 0.08, 0.4, 2, and 10 mg/kg, placebo group, and IgG 10-mg/kg group (n = 3, 4, 6, 6, 6, 6, and 4, respectively). (Biii) Proportion still parasitemic was analyzed by survival analysis, which showed the clean time of the complete elimination of parasites in mice with doses of HP6H8 at 0.016, 0.08, 0.4, 2, and 10 mg/kg, placebo group, and IgG group (n = 5, 5, 6, 6, 6, 8, and 6, respectively). (Ci) Parasitemia and (Cii) inhibition efficacy after the second infection with doses of HP6H8 at 0.016, 0.08, 0.4, 2, and 10 mg/kg, placebo group, and IgG group (n = 5, 5, 6, 6, 5, 5, and 3, respectively). (Ciii) Survival analysis of the proportion of mice remaining parasitemic; n = 6 for HP6H8 at 0.016 mg/kg and placebo groups; n = 5 for other groups. (D) Concentrations of HP6H8 in serum of engrafted and nonengrafted mice. (E) Positive rates of HP6H8-binding RBCs in engrafted mice.